Kimia Therapeutics employs an innovative technology known as ATLAS, which integrates AcTive® Learning with Automated Synthesis and Screening to enhance drug discovery. This approach utilizes machine learning to accelerate the identification of novel therapeutic targets and corresponding drug molecules, effectively creating a comprehensive chemical atlas of druggable space. By merging these advanced methodologies, Kimia aims to fundamentally transform the landscape of drug discovery, allowing for the rapid exploration of billions of target-directed compounds and generating extensive chemical and biological datasets.

In addition to ATLAS, Kimia's generative chemistry leverages iterative cycles of chemical design, high-throughput synthesis, and machine learning to map the intricate relationships between chemical structures and protein functions at a granular level. This process not only facilitates the creation of chemical maps for therapeutic intervention but also validates these maps through proteomic and gene editing technologies. The integration of machine learning into their workflow enables the identification of patterns within massive datasets, guiding future experimentation and leading to discoveries that were previously unattainable.

United States

Kimia Therapeutics is generating a chemical atlas for treating human disease. Kimia's ATLAS is the key to druggable space, unlocking the potential of generative chemistry. The company is focused on drug discovery and developing disease-modifying therapies for metabolic diseases.

Kimia Therapeutics

Company Details